Document vVebXv7XOQxVxpGk6epvMJa8b
2004 Asilomar Plenary Session Titles:
Speaker Jerry Rice Fu Hua
You-Xin Liang
Otto Wong Robert Schnatter Tom Armstrong
Richard Irons
Presentation Title
Recent Science & Ethics Review Panel Activity
Updating external review panel activities since last year's Asilomar conference ... feedback on study progress, protocol changes, and recruitment of two new bioethichsts
Building Institutional Relationships through the Shanghai Health Study
Update of organizational relationships in Shanghai, one year into data collection, with focus on Clinical Lab and Principal Investigator relationships with (and benefits to) Fudan University and the 27 allied hospitals.
QAlQC Approaches in Shanghai Health Study
Application of quality assurance & quality control (QAlQC) to disparate activities - exposure fieldwork, clinical laboratory analyses, and server-based data management - in CC, DP & ME studies (You-Xin now heads QAlQC assurance for the Shanghai Health Study).
Case-control study of AML and NHL in Shanghai
Overview & progress of CC study after 'a year of case accrual', highlighting issues in control selection process and in exposure reconstruction.
Molecular Epidemiology Studies in Shanghai
Overview & progress of ME study, highlighting ethical, political and regulatory issues in factory participation with quantitative documentation of 'worker overexposure' in Shanghai.
A Butcher, a Baker, a Candlestick Maker: An Overview of Jobs and Exposures in the Shanghai Studies
Exposure assessment and reconstruction for workers with different job classifications and within the same occupation in Shanghai
Shanghai Health Study - Clinical Aspects
Overview of DP & ME studies, with progress and issues updated after a year of case referrals to the new Clinical lab, highlighting clinical aspects of the study.
{ DATE \@ "M/d/yyyy" }
SH ELL-MCCLU RG-065335
SHANGHAI HEALTH STUDY ANNUAL MEETING 17-19 AUGUST 2004
DAY 1 - Tuesday, August 17 Morning I Afternoon 4:00 PM - 7:00 PM
5:30 PM - 6:30 PM 6:30 PM - 8:30 PM
Comments Travel Registration (Phoebe A. Hearst Social Hall)
Reception (Seascape)
Dinner (Seascape)
DAY 2 - Wednesday, August 18
7:30 AM - 8:30 AM 8:30 AM - 2:30 PM
Breakfast (dining room)
Plenary Session (Chapel) Co-Chairs: Patsy Clegg and Patrick Beatty
8:30 AM
Welcome and Introduction Patsy Clegg (Shell) Chair, Benzene Health Research Consortium Oversight Committee Dr. Patrick Beatty, Ph.D. (ChevronTexaco) Chair, Benzene Health Research Consortium Technical Committee
8:45AM 9:15 AM
Scientific Review Panel Activities Dr. Jerry Rice, Ph.D. (International Agency for Research on Cancer, retired) Chair, Scientific Review Panel
Ethics Review Panel Activities TBD Chair, Ethics Review Panel Dr. Fu Hua, MB, MPH, Ph.D. (Fudan University School of Public Health)
9:45AM
Case Control Study of AML and NHL in Shanghai Dr. Otto Wong, Sc.D. (Applied Health Sciences)
10:15 AM Tom Armstrong (ExxonMobil Biomedical Sciences)
10:45 AM 11 :00 AM
Break Dr. Robert Schnatter, Ph.D. (ExxonMobil Biomedical Sciences)
Asilomar Conference Center + 831/372-8016 + Monterey Peninsula + CA
SH ELL-MCCLU RG-065336
SHANGHAI
HEALTH STUDY ANNUAL MEETING 17-19 AUGUST 2004
11 :30 AM Dr. Liang You-xin, MD (Fudan University School of Public Health)
12:00 PM
Lunch (dining room)
1:00 PM - Clinical and Molecular Laboratory 2:30 PM Dr. Richard Irons, Ph.D. (University of Colorado)
2:45 PM - 5:00 PM
Panel Meetings (Sanderling)
2:45PM
Ethics Review Panel (ERP) Meeting (closed attendance)
3:45PM
Break
4:00 PM Scientific Review Panel (SRP) Meeting (closed attendance)
6:00 PM
Dinner (Barbeque Pit)
DAY 3 - Thursday, August 19 7:30 AM - 8:30 AM
Breakfast (dining room)
9:00 AM
Joint Panel I Investigator Meeting (closed attendance in Sanderling) Ethics Review Panel I Scientific Review Panel I Principal Investigators
10:00 AM 10:30 AM
12:00 PM 1:00 PM
Break
Joint Panel I Investigator Meeting continued (closed attendance in Sanderling) Ethics Review Panel I Scientific Review Panel I Principal Investigators
Plenary Session (Chapel)
Lunch (dining room)
2:30 PM
Annual Meeting Adjourned
Asilomar Conference Center + 831/372-8016 + Monterey Peninsula + CA SH ELL-MCCLU RG-065337
SHANGHAI HEALTH STUDY ANNUAL MEETING 17-19 AUGUST 2004
6:00 PM
DAY 4 - Friday, August 20
Dinner (dining room) Depart
Asilomar Conference Center + 831/372-8016 + Monterey Peninsula + CA SH ELL-MCCLU RG-065338
SHANGHAI HEALTH STUDY ANNUAL MEETING 17 - 19 AUGUST 2004
RESERVATION I REGISTRATION REQUEST
Title _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __ First Name: : Patsy __________________________ LastName:Clegg _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __ Name for Badge: Patsy Clegg______________________ Company or Affiliation: Shell Chemicals __________________ Address: 910 Louisiana St Houston, TX 77002,_ _ _ _ _ _ _ _ _ _ _ _ _ _ __
Phone: _713-241-2521 _ _ _ _ _ _ _ _ _ __ Fax: 713-241-3325 _ _ _ __ Email: patsy.clegg@shell.com ______________________ ACCOMMODATIONS: _x_ I I We plan to stay at Asilomar; please reserve a room.* I will arrive on: _Tues, Aug 17_ _ _ _ _ __ Depart on: Fri Aug 20 _ _ _ __ __I I We do not plan to stay at Asilomar and will make our own reservations.
ADDITIONAL GUESTS: First and Last Name: J.R. Clegg ______________________ (If you have children accompanying you, please supply their age)
SPECIAL EVENTS: Yes I No __ I I We will attend the Welcome Reception and dinner (Tuesday evening, Aug. 17th)
(# of adults _2_ # of children_ _) Yes I No_ _1 I We will attend the Cookout (Wednesday evening, Aug. 18th):
(# of adults _2_ # of children_ _) I ( have I do not have ) special needs. Please let us know how we can assist.
Please email to toddm@api.org or fax to Matthew Todd at 202-682-8031 no later than April 15th
* - Asilomar reservations are for August 17-19, 2004. Due to the Asilomar reservation policy, once you agree to reserve a room you will be responsible for payment even if you do not attend the meetings.
Asilomar Conference Center + 831/372-8016 + Monterey Peninsula + CA
SH ELL-MCCLU RG-065339
2004 SHANGHAI HEALTH STUDY ANNUAL MEETING ATTENDEES
Name Fu Hua Liang You-Xin Rob Schnatter Otto Wong Rich Irons Yimei Zhou Dick Albertini Harvey Checkoway John Cherrie Helmut Greim Rich Larson
Li Guilan
Jerry Rice Howard Rockette
Juhanna Idanpaan-Heikkila
Xu Zongliang
Liang Zhengliu
Ellen Clayton Paul Lombardo Mike Johnston Patsy Clegg Don Burnett Brian Doll Patrick Beatty Stuart Cagen Michael Bird Shan Tsai Chris Roythorne
Lynn Russo
Camille Costello
Laurie Labuda Geoff Granville
Lorraine Twerdok
Bruce Jarnot
Matt Todd
Madeleine Sellouk
Company / Organization Fudan University Fudan University ExxonMobil Biomedical Sciences Applied Health Sciences University of Colorado ExxonMobil University of Vermont University of Washington Institute of Occupational Medicine Technical University of Munich University of Chicago Chinese Center of Disease Control and Prevention Georgetown University Medical Center University of Pittsburgh
Council for Int'I Organization of Medical Sciences (CIOMS)
Center for Applied Ethics
Guest
Vanderbilt University University of Virginia ConocoPhillips Shell Chemical BP ExxonMobil Chevro nTexaco Shell Chemical ExxonMobil Shell Oil BP
ExxonMobil
Chevro nTexaco
APCO Shell Canada
API
API
API
API
Study Role Investigator Investigator Investigator Investigator Investigator Investigator Scientific Review Panel Scientific Review Panel Scientific Review Panel Scientific Review Panel Scientific Review Panel
Scientific Review Panel
Scientific Review Panel Scientific Review Panel
Ethics Review Panel
E-Mail hfu@shmu.edu.cn yxliang@shmu.edu.cn a. r. schnatter@exxonmobil.com ottowong@aol.com richard. irons@uchsc.edu yimei.x.zhou@exxonmobil.com ralbert315@aol.com checko@u.washington.edu john. cherrie@iomhg.org.uk helmut.greim@lrz.tum.de rlarson@medicine.bsd.uchicago.edu
guilanli@263.net.cn
jmricewas@aol.com herbst@(;1itt.edu juhana. idan(;1aan@(;1(;1.fimnet.fi idan(;1aanj@who.int
Phone 8621 64041900 8621 64043069 908-730-1101 650-347-7898 303-315-7196
802-656-8346 206-543-2052 4401314498032 498161715600 773 702-6783
86 1083132900
202-986-0659 412 624-3023
Ethics Review Panel Ethics Review Panel (translator) Ethics Review Panel Ethics Review Panel Sponsor - Oversight Sponsor - Oversight Sponsor - Oversight Sponsor - Oversight Sponsor - Technical Sponsor - Technical Sponsor - Technical Sponsor - Technical Sponsor - Technical Sponsor Communications Sponsor Communications Communications Sponsor Administrator Oversight Administrator Technical Administrator Communications Administrator Meetings
xzllzx@citiz.net
zhengliuliang@hotmail.com
ellen.w.clayj:on@vanderbilt.edu (;1aI8g@virginia.edu mike.d.johnston@conoco(;1hilli(;1s.com (;1atsy. clegg@shell.com burnettdm@b(;1.com brian.e.doll@exxonmobil.com (;1atrickbeatty@chevrontexaco.com stuart. cagen@shell.com michael.g. bird@exxonmobil.com shan.tsai@shell.com chris. royj:horne@uk.b(;1.com
lynn. b. russo@exxonmobil.com
86021 65643040
615-322-1186 434-982-4227 703 846-1199 713-241-2521 630-420-5093 703-846-2515 510242-7037 713-241-1407 908-730-1060 713-241-6078 207 496-4634
703-846-2500
ccaj@chevrontexaco.com
Ilabuda@a(;1coworldwide.com geoffrey.granville@shell.com
twerdokl@a(;1i.org
925-842-2583
202-659-7903 403-691-2220
202-682-8344
jarnotb@a(;1i.org
202-682-8473
toddm@a(;1i.org
202-682-8319
selloukm@a(;1i.org
202-682-8332
SH ELL-MCCLU RG-065340
2004 SHANGHAI HEALTH STUDY ANNUAL MEETING ATTENDEES
SH ELL-MCCLU RG-065341
A
1 2004 SHS Annual Meeting Attendees
2 3
4 5 Oversight 6 Mike Johnston 7 Patsy Clegg 8 Patrick Beatty 9 Don Burnett 10 Brian Doll 11 12 Com munications 13 Camille Costello 14 Lynn Russo 15 16 Technical 17 Chris Roythorne 18 Stu Cagen 19 Michael Bird 20 Shan Tsai 21 Jennifer Galvin 22
23 SRP 24 Dick Albertini 25 Harvey Checkoway 26 John Cherrie 27 Helmut Greim 28 Robert Herrick 29 Richard Larson 30 Guilan Li 31 Mark Minden 32 Jerry Rice 33 Howard Rockette 34 35 ERP 36 Juhana Idanpaan-Heikkila 37 Zongliang Xu 38 Zhengliu Liang (translator) 39 Ellen Clayton 40 Paul Lombardo 41
B C D E FG
email invite sent
email registration
sent
hard copy invite sent
hard copy registration
sent
registration received
3/25/2004 3/25/2004 3/25/2004 3/25/2004 3/25/2004
3/25/2004 3/25/2004 3/25/2004 3/25/2004 3/25/2004
NA NA NA NA NA
NA 3/29/2004 1
NA
4/112004
1
NA 3/30/2004 1
NA
4/812004
1
NA 5/10/2004 1
3/25/2004 3/25/2004
3/25/2004 3/25/2004
NA NA
NA 6/22/2004 1 NA 4/16/2004 1
3/25/2004 3/25/2004 3/25/2004 3/25/2004 3/26/2004
3/25/2004 3/25/2004 3/25/2004 3/25/2004 3/26/2004
NA NA NA NA NA
NA 3/26/2004 1 NA 4/14/2004 1 NA 4/15/2004 1 NA 4/15/2004 1 NA 4/14/2004 1
3/25/2004 3/25/2004 3/25/2004 3/25/2004 3/25/2004 3/25/2004 3/25/2004 3/25/2004 3/25/2004 3/25/2004
3/25/2004 3/25/2004 3/25/2004 3/25/2004 3/25/2004 3/25/2004 3/25/2004 3/25/2004 3/25/2004 3/25/2004
3/25/2004 3/25/2004 3/25/2004 3/25/2004 3/25/2004 3/25/2004 3/25/2004 3/25/2004 3/25/2004 3/25/2004
3/25/2004 3/25/2004 3/25/2004 3/25/2004 3/25/2004 3/25/2004 3/25/2004 3/25/2004 3/25/2004 3/25/2004
4/12/2004 3/29/2004 4/23/2004 4/112004 4/2112004 3/30/2004 4/27/2004 4/27/2004 4/312004 4/19/2004
1 1 1 1 1 1 1 1 1 1
3/25/2004 3/25/2004 5/3/2004 5/312004 5/312004
3/25/2004 3/25/2004 5/3/2004 5/3/2004 5/3/2004
3/25/2004 3/25/2004 5/3/2004 5/3/2004 5/3/2004
3/25/2004 3/25/2004 5/3/2004 5/3/2004 5/3/2004
4/2112004 4/26/2004 6/17/2004 5/24/2004 5/3/2004
1 1 1 1 1
SH ELL-MCCLU RG-065342
42 PI US 43 Rob Schnatter 44 Otto Wong 45 Rich Irons 46 Tom Armstrong 47 Yimei Zhou
48
49 PI-CHINA 50 Dr. Fu 51 Dr. Liang 52
53 others 54 Glenna Kyle 55 Myron Harrison 56 Geoff Granville 57
58 APCO 59 Laurie Labuda 60
61 API 62 Lorraine Twerdok 63 Paula Podhasky 64 Matt Todd 65 Bruce Jarnot 66 Madeleine Sellouk
67 TOTAL
A
B
4/7/2004 4/712004 4/712004 4/7/2004 4/26/2004
C
4/7/2004 4/7/2004 4/7/2004 4/7/2004 4/26/2004
D
4/8/2004 4/8/2004 4/8/2004 4/8/2004 4/26/2004
E FG
4/8/2004 4/8/2004 4/8/2004 4/8/2004 4/26/2004
4/15/2004 4/22/2004 ATTENDING 4/20/2004 5/17/2004
1 1 1 1 1
4/712004 4/712004
4/7/2004 4/7/2004
4/8/2004 4/8/2004
4/8/2004 4/8/2004
4/14/2004 4/15/2004
1 1
3/25/2004 6/712004
3/25/2004 6/7/2004
NA
6/10/2004 1 NA 4/19/2004 1
6/8/2004 1
3/25/2004 3/25/2004
NA
NA 4/15/2004 1
3/25/2004 3/25/2004 3/25/2004 3/25/2004 3/25/2004
3/25/2004 3/25/2004 3/25/2004 3/25/2004 3/25/2004
NA NA NA NA NA
NA 4/15/2004 1
NA NA
NA 4/15/2004 1
NA
40
SH ELL-MCCLU RG-065343
DRAFT Welcoming Remarks 2004 Annual Meeting SHS - Asilomar
Good morning. My name is Patsy Clegg. I am the Global Product Steward for Shell Chemicals... and this year I also have the honor of chairing the Oversight Committee of the Benzene Health Research Consortium.
I was happy to see that most everyone arrived in time for dinner last evening, and I hope that you all enjoyed yourselves as much as I did. I had a chance to speak with many of you individually and look forward to more of that during the rest of our stay together.
Along with my industry colleagues from BP, ChevronTexaco, ConocoPhillips, ExxonMobil, and Marathon, it is my sincere pleasure to welcome everyone back to Asilomar and thank you for joining us at this Second Annual Meeting of the Shanghai Health Study. As sponsors of the Study, we appreciate each of you taking the time out of your busy work - and, in some cases, vacation - schedules to be here for this important gathering.
1
SH ELL-MCCLU RG-065344
DRAFT Welcoming Remarks 2004 Annual Meeting SHS - Asilomar
While we have all traveled some distance to be here, I'd like to particularly thank our presenters here today -- many of whom have made the long journey from China to give us an update on their work. It is very good to see the now familiar faces of Professor Fu, Dr. Liang, Dr. Wong, Dr. Schnatter, Tom Armstrong and Dr. Irons. All of you, along with your many colleagues both here and in Shanghai are doing the "hard part" of this work and we truly appreciate your making the trip here to California once again.
In addition, I would like to extend a special welcome to the members of the Scientific Review Panel and the Ethics Review Panel who have joined us this year. With such an august group assembled we are looking forward, once again, to two days of well-informed and well-rounded discussions.
I know that I speak for others as well when I tell you how much I learned from each of you and from all of our panelists last year and I am eager to add to that knowledge base over the next two days.
2
SH ELL-MCCLU RG-065345
DRAFT Welcoming Remarks 2004 Annual Meeting SHS - Asilomar
We have made a great deal of progress over the past twelve months and I believe it is part of our "mission" here at Asilomar to take the time to step back and celebrate our successes.
But, of course there is still much to be done so I hope that we can also take advantage of this opportunity to build on that progress and success, to learn about where the project stands and to gain a bit of insight into the future of this important work.
Last year's meeting proved to be an invaluable opportunity for us to meet face-to-face to openly exchange information and ideas and ask questions about the progress of the project and the future of the Study.
The extent of the information-sharing, cooperation and mutual respect we have experienced at all levels, has demonstrated the real strength of this effort - the strong collaborative relationships that have developed among the researchers, the Scientific Review Panel, the Ethics Review Panel and the industry sponsors. The strength of these relationships and our mutual commitment to the scientific
3
SH ELL-MCCLU RG-065346
DRAFT Welcoming Remarks 2004 Annual Meeting SHS - Asilomar
work that is underway is an important building block for success and can't be overlooked going forward.
This is an ambitious effort and we've successfully navigated a number of challenges to get where we are today. Throughout this process, we have learned that by working together and utilizing the scientific and ethical checks and balances that we've put in place we have built a strong foundation for collaboration and success. I am confident that together we can meet any future challenges that may come our way.
We still have a long road ahead of us, but we've passed a number of important milestones together over the past twelve months.
When we met last year, Dr. Irons showed us photographs of the laboratory at Fudan University. The finishing touches were being added to the lab and it was only just beginning to get up and running. In December, we celebrated the launch of the laboratory which is now a fully operational, state-of-the art diagnostic and clinical facility running at full capacity.
4
SH ELL-MCCLU RG-065347
DRAFT Welcoming Remarks 2004 Annual Meeting SHS - Asilomar
Dr. Irons and Dr. Fu have also worked very had to establish collaborative relationships between Fudan University and the 27 allied hospitals in Shanghai. This level of cooperation is remarkable and I know Dr. Irons has said he doesn't think it could have been done in the U.S. Their success in bringing these allies together is truly impressive and it is a clear measure of both the importance of the Study and the high esteem to which the medical community in Shanghai holds their work. Likewise, I'd also like to underscore how appreciative we, as sponsors of the study, are to the collaborators in China who have helped to guide us through the various challenges we faced when confronted with the unfamiliar culture and environment in China. We could not have accomplished this on our own.
With the lab facilities up and running and the promise of close collaboration with Shanghai's hospital and medical communities, the study is well underway. We look forward to hearing more from the investigators today about the specifics of their work, the progress that has been made over the past year and what we can look forward to in the months - and even years - ahead.
5
SH ELL-MCCLU RG-065348
DRAFT Welcoming Remarks 2004 Annual Meeting SHS - Asilomar
In industry terms, we've taken big steps forward - from planning through project execution and now to being fully operational But being "fully operational" does not mean that we can relax and wait for the results to come rolling in, we appreciate that there is much still to be done.
We all know from experience - some of us better than others - that the path to good science isn't always clear and it's almost never quick. We all recognize that this is a multiyear effort and we are committed to seeing it through.
The tranquility of the environment here at Asilomar - without the usual distractions and diversions that most of are used to encountering - made for a very productive and informative meeting last year - something that we hope to replicate again over the next two days.
With the help of the staff and counsel of API we have come together around a fairly ambitious program similar in format to our meeting last year. It is our hope that the plenary sessions will provide a useful framework for all of us to share our experiences and seek and receive support in resolving
6
SH ELL-MCCLU RG-065349
DRAFT Welcoming Remarks 2004 Annual Meeting SHS - Asilomar
any problems from the vast scientific intellect that have gathered here. Let me thank you once again for joining us, we are all looking forward to a successful two days ahead. With that in mind, I'm eager to listen and learn so I'd like to introduce our colleague and friend Dr. Patrick Beatty of ChevronTexaco, chair of the Consortium's Technical Committee, who will be our moderator for the day's meeting. Patrick
7 SH ELL-MCCLU RG-065350
Welcoming Remarks 2004 SHS Annual Meeting - Asilomar
Good morning. My name is Patsy Clegg. I am the Product Steward for Shell Chemicals and this year I also have the honor of chairing the Oversight Committee of the Benzene Health Research Consortium.
I was happy to see that most everyone arrived in time for dinner last evening, and I hope that you all enjoyed yourselves as much as I did. I had a chance to speak with many of you individually and look forward to more of that during the rest of our stay together.
Along with my industry colleagues from BP, ChevronTexaco, ConocoPhillips, ExxonMobil, and Marathon, it is my sincere pleasure to welcome everyone back to Asilomar and thank you for joining us at this Second Annual Meeting of the Shanghai Health Study. As sponsors of the Study, we appreciate each of you taking the time out of your busy work - and, in some cases, vacation - schedules to be here for this important gathering. While we have all traveled some distance to be here, I'd like to particularly thank our presenters here today -- many of whom have made the long journey from China to give us an update on their work. It is
1
SHELL-MCCLURG-065351
Welcoming Remarks 2004 SHS Annual Meeting - Asilomar
good to see the now familiar faces of Professor Fu, Dr. Liang, Dr. Wong, Dr. Schnatter, Tom Armstrong and Dr. Irons. All of you, along with your many colleagues both here and in Shanghai are doing the "hard part" of this work and we truly appreciate your making the trip here to California once again.
In addition, I would like to extend a special welcome to the members of the Scientific Review Panel and the Ethics Review Panel who have joined us this year. With such an august group assembled we are looking forward, once again, to two days of well-informed and well-rounded discussions.
I know that I speak for others as well when I tell you how much I learned from each of you and from all of our panelists last year and I am eager to add to that knowledge base over the next two days.
We have made a great deal of progress over the past twelve months and I believe it is part of our "mission" here at Asilomar to take the time to step back and celebrate our successes.
2
SH ELL-MCCLU RG-065352
Welcoming Remarks 2004 SHS Annual Meeting - Asilomar
But, of course there is still much to be done so I hope that we can also take advantage of this opportunity to build on that progress, to learn about where the project stands and to gain a bit of insight into the future of this important work.
Last year's meeting proved to be an invaluable opportunity for us to meet face-to-face to openly exchange information and ideas and ask questions about the progress of the project and the future of the Study.
The extent of the information-sharing, cooperation and mutual respect we have experienced at all levels, has demonstrated the real strength of this effort - the strong relationships and dialogue that have developed among the researchers, the Scientific Review Panel, and the Ethics Review Panel. The strength of these relationships and our mutual commitment to the scientific work that is underway is an important building block for success and can't be overlooked going forward.
This is an ambitious effort and we've successfully navigated a number of challenges to get where we are today.
3
SH ELL-MCCLU RG-065353
Welcoming Remarks 2004 SHS Annual Meeting - Asilomar
Throughout this process, we have learned that by working together and utilizing the scientific and ethical checks and balances that we've put in place we have built a strong foundation for collaboration and success. I am confident that together we can meet any future challenges that may come our way.
We still have a long road ahead of us, but we've passed a number of important milestones together over the past twelve months.
When we met last year, Dr. Irons showed us photographs of the laboratory at Fudan University. The finishing touches were being added to the lab and it was only just beginning to get up and running. In December, we formally recognized the launch of the laboratory which is now a fully operational, state-of-the art diagnostic and clinical facility operating at full capacity.
Dr. Irons and Dr. Fu have also worked very had to establish collaborative relationships between Fudan University and the 27 allied hospitals in Shanghai. This level of cooperation is remarkable and I know Dr. Irons has said he doesn't think it
4
SH ELL-MCCLU RG-065354
Welcoming Remarks 2004 SHS Annual Meeting - Asilomar
could have been done in the U.S. Their ability to bring these allies together is truly impressive and it is a clear measure of both the importance of the Study and the high esteem to which the medical community in Shanghai holds their work. Likewise, I'd also like to underscore how appreciative we, as sponsors of the study, are to our collaborators in China who have helped to guide the project through the various challenges presented by the unfamiliar culture and environment in China. We could not have accomplished this on our own.
With the lab facilities up and running and the promise of close collaboration with Shanghai's hospital and medical communities, the study is well underway. We look forward to hearing more from the investigators today about the specifics of their work, the progress that has been made over the past year and what we can look forward to in the months - and even years - ahead.
In industry terms, we've taken big steps forward - from planning through project execution and now to being fully operational But being "fully operational" does not mean that
5
SH ELL-MCCLU RG-065355
Welcoming Remarks 2004 SHS Annual Meeting - Asilomar
we can relax and wait for the results to come rolling in, we appreciate that there is much still to be done.
We all know from experience - some of us better than others - that the path to good science isn't always clear and it's almost never quick. We all recognize that this is a multiyear effort and we are committed to seeing it through. To me, the result we get will be worth the wait. I mentioned earlier that I'm the Product Steward for Shell Chemical. My company, along with the other sponsors of this study, believes that the better we understand the potential effects of exposure to benzene, the better equipped we are to put in place controls to minimize risk. As part of our ongoing commitment to product stewardship, we believe that the insights and understanding we will gain from this study will be important to help ensure that we are effectively managing and minimizing risk.
The tranquil environment at Asilomar - without the usual distractions and diversions that most of are used to encountering - made for a very productive and informative meeting last year - something that we hope to replicate again over the next two days.
6
SH ELL-MCCLU RG-065356
Welcoming Remarks 2004 SHS Annual Meeting - Asilomar
With the help of the API staff, we have come together for an ambitious program similar in format to our meeting last year. It is our hope that the plenary sessions will provide a useful framework for all of us to share our experiences and seek and receive support in resolving any problems from the vast scientific intellect that has gathered here. Let me thank you once again for joining us, we are all looking forward to a productive two days. With that in mind, I'm eager to listen and learn so I'd like to introduce our colleague and friend Dr. Patrick Beatty of ChevronTexaco, chair of the Consortium's Technical Committee who will be our moderator for the day's meeting. Patrick....
7 SH ELL-MCCLU RG-065357
SHANGHAI HEALTH STUDY
American Petroleum Institute SHS Administrator 1220 L Street, NW Washington, DC 20005-4070 Tel: 202-682-8344 Fax: 202-682-8031 E-mail: twerdokl@api.org
January XX, 2005
Name of Individual Title Address Line 1 Address Line 2
Dear ---------- [SHS Annual Meeting Participant]
The Shanghai Health Study Oversight Committee has been developing preliminary plans for the 2005 Annual Meeting and would like to announce a change of venue for the meeting from Shanghai to Fairfax, Virginia, USA, which is a suburb of Washington, DC.
Dates: Location: Hotel:
Tuesday, November 1 - Thursday, November 3,2005 ExxonMobil Conference Facilities, Fairfax, Virginia Tysons Corner Ritz Carlton
The meeting would begin with dinner on Tuesday and conclude Thursday. Please hold these dates. [no para} The meeting will follow a similar format as previous meetings. Wednesday will be a plenary session where the investigators will present reports on study progress. This will take most of the day to allow time for questions and answers. Thursday will be the opportunity for the Scientific and Ethic Review Panels to meet, both on their own and with the investigators. I want to thank Dr. Fu and his team in China for offering to host our meeting and apologies to all for our change in plansWe look forward to an exciting and successful annual meeting. Agenda, registration and logistical information to be provided as it is developed.
Sincerely,
Patsy Clegg, Product Steward A@@4tQr@qhl@$tPt"@tt#M:\4t~tt@$] Chair, Oversight Committee
Administrative support provided by The American Petroleum Institute 1220 L Street, Northwest
Washington, DC 20005-4070
SH ELL-MCCLU RG-065358